University of Thessaly (UTH)
Επιδράσεις επιγενετικών φαρμάκων στα CD3+ CD8+ κυτταρολυτικά κύτταρα ασθενών με καρκίνο
Abstract
dc:descriptionOBJECTIVE: This study aimed to investigate the effects of epigenetic drugs on antitumor peptide-specific CD8+ CTL clones isolated from patients with NSCLC and melanoma.MATERIALS AND METHODS: Three peptide-specific CD8+ CTL clones against hTERT and MAGE, isolated from patients with NSCLC and melanoma respectively were enrolled in this study. Four cancer cell lines, EBV transformed B cells and PBMCs were used as antigen presenting and feeder cells. The CTL clones were cultured in the presence of 5-aza-CdR and TSA and the alterations in the phenotypic, lytic, functional characteristics as well as in gene expression were investigated. Lytic capability was determined by standard chromium release assay and cell cycle kinetics was analysed using BrdU uptake. Apoptosis assay was performed using Annexin/7-AAD and the extracellular and intracellular protein expression was determined using flow cytometry. Gene expression was performed using quantitative RT-Real Time PCR.RESULTS: The epigenetic drugs had an immunomodulatory effect on antitumor peptide-specific CTL. It was confirmed that 5-aza-CdR decreased the global DNA methylation level of CTL by 47% and that the subtoxic concentrations did not affect the cell cycle. FAS cell surface expression was found to be increased by 47% whereas no significant change was observed in the expression of CD8, CD25, CD27, CD28, CD57 ,CD62L, CCR7, CD69, CD122, CD127 and CD178. CTL clones cultured in the presence of 5-aza-CdR exhibit a significant decrease in their cytolytic capabilities (up to70%) that is maintained after drug removal and a subsequent cycle of stimulation and culture (up to 90%). The molecular analysis of the clones against hTERT and MAGE determined that 5-aza-CdR increased gene expression with a fold change of 8 and 15.2 for FOXP3, 3.9 and 2.2 for FASL, 5.3 and 1.8 for FAS, 1.8 and 6.1 for TNF, 4.2 and 4.1 for PD-L1, 4.3 and 4.7 for PD-L2 respectively. No significant differences were observed for PERFORIN, GRANZYMEB, IFNG, IL1b, IL10, TNFSF10, TGFb1, TGFb3, TGFbR1, PD-1, SMAD2, SMAD3, SMAD4 and SMAD7. TSA was found to dramatically decrease the clone activation capability (up to 95.3%) in a dose-dependent manner as well as the clone lytic capability (up to 48.3%).CONCLUSION: The effects of epigenetic drugs on antitumor peptide-specific CD8+ CTL clones are multifaceted and it is difficult to produce definitive conclusions. Howbeit, the immunomodulatory effects observed with most prominent being a severely compromised lytic ability against targets presenting tumor peptides, lead to a phenotype with reduced ability to lyse target cancer cells.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Boukas, Konstantinos
- Μπούκας, Κωνσταντίνος
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41916